Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA effects on affective touch in autistic traits
NCT04053036Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Aug 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of midomafetamine in Autism Spectrum Disorder (ASD) (2 arms), sponsored by University of Chicago. Primary endpoint: Change in Responses to Affective Touch. Started Aug 2019; status: completed.
02
Drugs
midomafetamine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04053036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053036.